| 程序死亡受体1抗体治疗18例晚期肿瘤患者的临床疗效观察及文献复习 |
| 投稿时间：2016-04-28 修订日期：2016-12-07 点此下载全文 |
| 引用本文：夏涌,寇晓霞,杨喜晶,周福平,张迁,钱其军.程序死亡受体1抗体治疗18例晚期肿瘤患者的临床疗效观察及文献复习[J].药学实践杂志,2017,35(2):174~177 |
| 摘要点击次数: 1371 |
| 全文下载次数: 966 |
|
|
| 中文摘要:目的 观察程序死亡受体1（programmed death-1，PD-1）抗体治疗晚期肿瘤患者的免疫疗效。方法 选取东方肝胆外科医院生物治疗科2015年10月至2016年3月的18例晚期肿瘤患者，给予PD-1抗体静滴治疗。观察患者治疗前后的临床疗效、不良反应及无进展生存期，并对治疗前后患者的生活质量进行对比。结果 患者经PD-1抗体治疗后，PR 5例、SD 7例、PD 6例，生活质量KPS评分较治疗前明显上升（P<0.05）。至随访结束，共有5例死亡，2例失访，11例存活，中位无进展生存期为2.6个月（95% CI：1.8~3.3个月），无严重不良反应和化验指标异常。结论 PD-1抗体是治疗晚期肿瘤安全有效的治疗方法，不良反应少，临床耐受良好，但该结论仍有待进一步大样本随机对照研究证实。 |
| 中文关键词:PD-1抗体 晚期肿瘤 肿瘤免疫治疗 |
| |
| Clinical observation and literature review of PD-1 antibody in the treatment of 18 patients with advanced tumor |
|
|
| Abstract:Objective To observe the immune effect of PD-1 (programmed death-1) antibody in the treatment of patients with advanced cancer.Methods From October 2015 to March 2016, 18 patients with advanced tumor were selected to receive the PD-1 antibody treatment in Eastern Hepatobiliary Surgical Hospital. Clinical efficacy, adverse reactions and progression free survival time were monitored. The quality of life were compared before and after the treatment.Results Among 18 cases, PR 5 cases, SD 7 cases and PD 6 cases. The KPS scores for quality of life was significantly increased (P<0.05) after treatment. At the end of follow-up, 5 patients died, 2 patients were lost in follow-up, 11 patients survived. The median progression free survival was 2.6 months (95% CI:1.8-3.3 months). No serious adverse reactions and abnormal laboratory results were reported.Conclusion PD-1 antibody is a safe and effective treatment for advanced tumors. It is well tolerated and has less adverse reactions. The randomized control studies with larger samples are needed to further confirm our conclusions. |
| keywords:PD-1 antibody advanced tumor tumor immunotherapy |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
